Tacrolimus
Indication
For prophylaxis of graft rejection
Brand:
Dailiport
Nice TA:
Commissioning responsibility:
CCG (HRG included)
PbR excluded:
No
Background
Dailiport modified release oral capsules are recommended for all patients who are newly prescribed modified release tacrolimus for transplant rejection – RAG status RED for new patients
Please note:
Dailiport modified release capsules are not bioequivalent to Adoport immediate release capsules and do not replace Adoport capsules.
Existing patients using Advagraf modified release capsules will remain on Advagraf and are not routinely switched to Dailiport. If a prescriber considers that switching a patient to a different brand of oral tacrolimus would be of benefit, the change requires careful supervision and therapeutic monitoring by an appropriate specialist.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine